Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
G Alter, J Yu, J Liu, Abishek Chandrashekar et autres
The Ad26.COV2.S vaccine1-3 has demonstrated clinical efficacy against symptomatic COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing antibodies1. However, the immunogenicity of this vaccine in humans against SARS-CoV-2 variants of concern remains unclear. Here we report humoral and …